AzTrials
AzTrials

SeizuresPhase 3NCT00319501

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

A Phase 3 study testing Vanquix Auto-Injector (Diazepam Injection) in people with Seizures and Epilepsies, Partial, run by Pfizer at 86 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To evaluate the efficacy and safety of diazepam in the management of refractory epilepsy in selected patients who require intermittent medical intervention for the control of episodes of acute repetitive seizures. Read more about this study

Who is it for?
Ages 2 years and older
What is being tested?
Vanquix Auto-Injector (Diazepam Injection)
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
234 participants
Where
86 sitesUnited States
Study dates
Jan 2006to Jul 2014
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • For Patient:
  • Older than 2 years of age and between 6 and 136 kg body weight
  • Recipient of clinical diagnosis of epilepsy, taking a stable antiepileptic drug regimen for at least 2 weeks, and requiring intermittent medical intervention to control episodes of acute repetitive seizures (ARS)
  • Experienced at least 2 episodes of ARS in previous year, one of which occurred in previous 6 months
  • Has episodes of ARS that include complex partial or generalized seizures
  • Has a responsible caregiver available to participate
Show all 14Show fewer
  • Is not pregnant or lactating and is practicing an acceptable method of birth control.
  • For Caregiver:
  • Age of 18 years or older and has demonstrated responsibility as a caregiver through training to:
  • Recognize an episode of repetitive seizures for which the injection was intended,
  • Administer study drug
  • Count and record seizures and respiratory rate in the patient diary,
  • Monitor the patient and record observations in the patient diary for 12 hours following study drug treatment
  • Recognize the need for immediate medical attention.

Who cannot join

  • For Patient:
  • Petit mal status or petit mal variant status
  • History of ARS consistently progressing to status epilepticus
  • History of failure to respond to benzodiazepine treatment
  • Hypersensitivity to diazepam
  • Acute narrow angle glaucoma
Show all 9Show fewer
  • Alcohol and/or other substance abuse
  • Has taken another investigational drug in previous 30 days
  • Acute or progressive neurologic or severe psychiatric disease or severe mental abnormality.

Trial locations and contacts

86 sites in 1 country.

86 sites in 1 country

United States86 sites
  • Child Neurology Associates, PC

    Atlanta, Georgia, 30342

  • Consultants in Epilepsy and Neurology, PLLC

    Boise, Idaho, 83702

  • Bradenton Research Center, Inc.

    Bradenton, Florida, 34205

  • Elmwood Clinic

    Buffalo, New York, 14207

  • Millard Fillmore Gates Hospital/Comprehensive Epilepsy Center

    Buffalo, New York, 14209

  • Women and Children's Hospital of Buffalo

    Buffalo, New York, 14222

  • Lahey Clinic Medical Center

    Burlington, Massachusetts, 01805

  • Medical University of South Carolina Hospitals and Clinics

    Charleston, South Carolina, 29425

  • Medical University of South Carolina/Department of Pharmacy Service

    Charleston, South Carolina, 29425

  • Medical University of South Carolina

    Charleston, South Carolina, 29425

  • The Comprehensive Epilepsy Care Center For Children and Adults

    Chesterfield, Missouri, 63017

  • Comer Children's Hospital

    Chicago, Illinois, 60637

  • University of Chicago Hospital Pharmacy

    Chicago, Illinois, 60637

  • University of Chicago Medical Center (UCMC) Center for Advanced Medicine (CAM)

    Chicago, Illinois, 60637

  • University of Chicago Medical Center (UCMC)

    Chicago, Illinois, 60637

  • Morton Plant Hospital Epilepsy Clinic

    Clearwater, Florida, 33756

  • Morton Plant Hospital Pharmacy

    Clearwater, Florida, 33756

  • The Cleveland Clinic Foundation

    Cleveland, Ohio, 44195-5102

  • The Cleveland Clinic Health Systems

    Cleveland, Ohio, 44195-5102

  • Ohio State University Neurology Clinic

    Columbus, Ohio, 43210

  • Ohio State University University Hospital

    Columbus, Ohio, 43210

  • Ohio State University

    Columbus, Ohio, 43210

  • Neurological Clinic of Texas, PA

    Dallas, Texas, 75230

  • Cook Children's Medical Center Office of Grants and Research

    Fort Worth, Texas, 76104

  • Cook Children's Medical Center

    Fort Worth, Texas, 76104

  • Cook Children's Physcian Network

    Fort Worth, Texas, 76104

  • Mid-South Physicians Group, PLLC

    Germantown, Tennessee, 38138

  • Clinical Research Center of New Jersey

    Gibbsboro, New Jersey, 08026

  • Cone Health Child Neurology

    Greensboro, North Carolina, 27401

  • Guilford Neurologic Associates

    Greensboro, North Carolina, 27405

  • Child Neurology Center of NorthWest Florida

    Gulf Breeze, Florida, 32561

  • NorthWest Florida Clinical Research Group, LLC

    Gulf Breeze, Florida, 32561

  • Stein Life Child Neurology Medical Specialists Inc.

    Irvine, California, 92606

  • MRI Location

    Kansas City, Missouri, 64111

  • St Luke's Hospital Neurological Consultants

    Kansas City, Missouri, 64111

  • St Luke's Hospital

    Kansas City, Missouri, 64111

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire, 03756

  • Emery Neuroscience Center

    Lighthouse PT, Florida, 33064

  • Clinical Trials, Inc

    Little Rock, Arkansas, 72205

  • Collaborative NeuroScience Network, LLC

    Long Beach, California, 90806

  • University Neurologists PSC Pediatric Division

    Louisville, Kentucky, 40202

  • University of Louisville Ambulatory Care Building Clinic

    Louisville, Kentucky, 40202

  • University of Louisville Clinical Trials Unit

    Louisville, Kentucky, 40202

  • Pediatric Neurology and Epilepsy Center

    Loxahatchee Groves, Florida, 33470

  • University of Tennessee Lebonheur Pediatric Specialists Inc.

    Memphis, Tennessee, 38103

  • Miami Children's Hospital

    Miami, Florida, 33155

  • Access Clinical Trial, Inc.

    Nashville, Tennessee, 37203

  • CMC - Physician's Park

    Nashville, Tennessee, 37203

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232-2551

  • Vanderbilt Epilepsy Clinic

    Nashville, Tennessee, 37232

  • Vanderbilt University Hospital Pharmacy

    Nashville, Tennessee, 37232

  • University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical Group

    New Brunswick, New Jersey, 08901

  • University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School

    New Brunswick, New Jersey, 08901

  • NYU Medical Center, Comprehensive Epilepsy Center

    New York, New York, 10016

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California, 92658

  • Brain and Spine Surgeons of Orange County

    Newport Beach, California, 92663

  • Neurology Clinic, PC

    Northport, Alabama, 35476

  • The Neurology and Pain Clinic

    Orangeburg, South Carolina, 29118

  • EKG only

    Orlando, Florida, 32806

  • Pediatric Neurology, PA

    Orlando, Florida, 32819

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104

  • St. Christopher's Hospital for Children

    Philadelphia, Pennsylvania, 19134-1095

  • St. Christopher's Hospital for Children

    Philadelphia, Pennsylvania, 19134

  • North Pacific Epilepsy Research/The Northrup Center

    Portland, Oregon, 97210

  • Raleigh Neurology Associates, PA

    Raleigh, North Carolina, 27607

  • Virginia Commonwealth University Health System

    Richmond, Virginia, 23298-0042

  • Virginia Commonwealth University Division of Child Neurology

    Richmond, Virginia, 23298-0211

  • Virginia Commonwealth University Ambulatory Care Center/Department of Neurology

    Richmond, Virginia, 23298-0599

  • Strong Memorial Hospital

    Rochester, New York, 14642

  • University of Rochester, Strong Epilepsy Center

    Rochester, New York, 14642

  • Drug Shipment

    Sacramento, California, 95816

  • Sacramento Comprehensive Epilepsy Program

    Sacramento, California, 95816

  • Sutter Cancer Center Specialty Clinic

    Sacramento, California, 95816

  • Sutter Institute for Medical Research

    Sacramento, California, 95816

  • Northern California Cardiology

    Sacramento, California, 95819

  • Neurology Clinic of St Cloud

    Saint Cloud, Minnesota, 56303

  • Alamo City Clinical Research, LLC

    San Antonio, Texas, 78258

  • Savannah Neurology, PC

    Savannah, Georgia, 31405

  • Harborview Medical Center

    Seattle, Washington, 98104

  • University of Washington Regional Epilepsy Center, Harborview Medical Center

    Seattle, Washington, 98104

  • AMO Corp

    Tallahassee, Florida, 32308

  • Tallahassee Neurological Clinic

    Tallahassee, Florida, 32308

  • Pediatric Epilepsy & Neurology Specialists

    Tampa, Florida, 33609

  • Willsey Research Inc

    Tampa, Florida, 33613

  • Wellspan Neurosciences

    York, Pennsylvania, 17402

  • Apple Hill Medical Center (EKG & Lab Draw)

    York, Pennsylvania, 17403

Other trials in United States

About this study

Official title: A Phase 3, Randomized, Double-blind, Parallel, Placebo-controlled, Multicenter Study, With Optional Open-label Continuation, Of The Efficacy And Safety Of Vanquix(tm) Auto-injector (Diazepam Injection) For The Management Of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Medical Intervention To Control Episodes Of Acute Repetitive Seizures

To evaluate the efficacy and safety of diazepam in the management of refractory epilepsy in selected patients who require intermittent medical intervention for the control of episodes of acute repetitive seizures. In addition, to assess the support provided by caregivers who are not themselves or not under the direct supervision of health care professionals at the time of administration.

Being tested
Placebo, Vanquix Auto-Injector (Diazepam Injection)
Keywords
Acute Repetitive Seizures, ARS, Diazepam, Cluster Seizures
Medical subject headings
Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PlaceboDrug

    Intramuscular autoinjector; administered at onset of an episode

  • Vanquix Auto-Injector (Diazepam Injection)Drug

    Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode

Study groups in NCT00319501
Study groupRoleWhat they receive
PlaceboPlacebo comparatorDuring the Double-blind Period, participants received a single, age- and weight-appropriate dose of placebo solution as a deep intramuscular injection in the mid to outer thigh. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of acute repetitive seizures (ARS).
Receives: Drug: Placebo
DiazepamExperimentalDuring the Double-blind Period, participants received a single, age- and weight-appropriate dose of diazepam solution, ranging from 0.2 to 0.5 mg/kg, as a deep intramuscular injection in the mid to outer thigh. Additional doses were permissible during the Open-label Period. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of ARS.
Receives: Drug: Vanquix Auto-Injector (Diazepam Injection)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to Next Seizure or Rescue Medication During the Double-blind Period (Kaplan-Meier 50th Percentile)

    An event was defined as an episode of or required rescue medication for an episode of acute repetitive seizures (ARS) within 15 minutes to 12 hours following study drug administration. Patients without an ARS event were censored at 12 hours. Diaries were provided; if no diary was returned, or the diary did not provide answers to questions about seizures and rescue during the 12-hour follow-up period, the patient was considered censored as of 15 minutes past the treatment time, unless another contact was documented. If seizure control following study drug administration was inadequate, diazepam rectal gel was provided as a rescue medication, given only in the first 4 hours after study drug administration and only if the caregiver was directed to do so by the Investigator or designee at the time of the ARS episode. Patients and their caregivers were trained to recognize the onset of an episode of ARS and when and how to administer study drug.

    Measured: From 15 minutes to 12 hours after study drug administration for an episode of ARS during the Double-blind Period

  2. Percentage of Participants With an Event (Next Seizure or Rescue Medication) During the Open-label Period

    An event was defined as an episode of or required rescue medication for an episode of acute repetitive seizures (ARS) within 15 minutes to 12 hours following study drug administration. Patients without an ARS event were censored at 12 hours. Diaries were provided; if no diary was returned, or the diary did not provide answers to questions about seizures and rescue during the 12-hour follow-up period, the patient was considered censored as of 15 minutes past the treatment time, unless another contact was documented. If seizure control following study drug administration was inadequate, diazepam rectal gel was provided as a rescue medication, given only in the first 4 hours after study drug administration and only if the caregiver was directed to do so by the Investigator or designee at the time of the ARS episode. Patients and their caregivers were trained to recognize the onset of an episode of ARS and when and how to administer study drug.

    Measured: From 15 minutes to 12 hours after study drug administration for an episode of ARS during the Double-blind Period

Secondary outcomes (10)
  1. Number of Participants Requiring Rescue Medication During the Double-blind Period

    If seizure control following study drug administration was inadequate, diazepam rectal gel was provided as a rescue medication, given only in the first 4 hours after study drug administration and only if the caregiver was directed to do so by the Investigator or designee at the time of the acute repetitive seizure (ARS) episode. Each patient's specific criteria for seizure and an episode of ARS were determined by the Investigator. Patients and their caregivers were trained to use these criteria to recognize the onset of an episode of ARS and when and how to administer study drug. An episode of ARS was defined as an episode of multiple complex, partial, or generalized seizures occurring over a brief period (minutes to 12 hours) with the patient regaining consciousness between seizures, which were readily recognizable by the patient or a trained caregiver. ARS includes seizures sometimes referred to as serial, cluster, crescendo, or stuttering prolonged.

    Measured: From 15 minutes to 12 hours following study drug administration for an episode of ARS during the Double-blind Period

  2. Number of Participants Requiring Emergency Department Visits During the Double-blind Period

    Any use of emergency treatment (such as an emergency room visit) was recorded in the patient's diary, along with the date, time, and reason for the emergency treatment. Emergency department visits required some type of rescue action taken, other than the visit itself. An episode of acute repetitive seizures (ARS) was defined as an episode of multiple complex, partial, or generalized seizures occurring over a brief period (minutes to 12 hours) with the patient regaining consciousness between seizures, which were readily recognizable by the patient or a trained caregiver. ARS includes seizures sometimes referred to as serial, cluster, crescendo, or stuttering prolonged.

    Measured: From 15 minutes to 12 hours following study drug administration for onset of an episode of ARS during the Double-blind Period

  3. Number of Participants Requiring Rescue Medical Care Other Than Rescue Medication or Emergency Department Visits During the Double-blind Period

    Other rescue medical care consisted of care other than rescue medication or emergency department visits. Each patient's specific criteria for seizure and an episode of acute repetitive seizure (ARS) were determined by the Investigator. Patients and their caregivers were trained to use these criteria to recognize the onset of an episode of ARS and when and how to administer study drug. An episode of ARS was defined as an episode of multiple complex, partial, or generalized seizures occurring over a brief period (minutes to 12 hours) with the patient regaining consciousness between seizures, which were readily recognizable by the patient or a trained caregiver. ARS includes seizures sometimes referred to as serial, cluster, crescendo, or stuttering prolonged.

    Measured: From 15 minutes to 12 hours following study drug administration for an episode of ARS during the Double-blind Period

  4. Mean Score on Caregiver Global Treatment Assessment During the Double-blind Period

    Caregiver global evaluation is based on seizure frequency, severity, and overall outcome compared with previous episodes and is rated on a 10-cm visual analogue scale, where 0=much worse and 10=much better. A higher score indicates greater improvement. An episode of acute repetitive seizures (ARS) is defined as an episode of multiple complex, partial, or generalized seizures occurring over a brief period (minutes to 12 hours) with the patient regaining consciousness between seizures, which were readily recognizable by the patient or a trained caregiver. ARS includes seizures sometimes referred to as serial, cluster, crescendo, or stuttering prolonged.

    Measured: Assessments completed at the end of each treated episode of ARS in the Double-blind Period

  5. Mean Score on Physician Global Treatment Assessment During the Double-blind Period

    Physician global evaluation is based on seizure frequency, severity, and overall outcome compared with previous episodes. The physician global evaluation is rated on a 10-cm visual analogue scale, where 0=much worse and 10=much better. A higher score indicates greater improvement. An episode of acute repetitive seizures (ARS) was defined as an episode of multiple complex, partial, or generalized seizures occurring over a brief period (minutes to 12 hours) with the patient regaining consciousness between seizures, which were readily recognizable by the patient or a trained caregiver. ARS includes seizures sometimes referred to as serial, cluster, crescendo, or stuttering prolonged.

    Measured: At Visit 2 and subsequent visits in the Double-blind Period

  6. Number of Participants Requiring Rescue Medication During the Open-label Period

    Each patient's specific criteria for seizure and an episode of acute repetitive seizure (ARS) were determined by the Investigator. Patients and their caregivers were trained to use these criteria to recognize the onset of an episode of ARS and when and how to administer study drug. If seizure control following study drug administration was inadequate, diazepam rectal gel was provided as a rescue medication, given only in the first 4 hours after study drug administration and only if the caregiver was directed to do so by the Investigator or designee at the time of the ARS episode.

    Measured: From 15 minutes to 12 hours after study drug administration during the Open-label Period

  7. Number of Participants Requiring Emergency Department Visits During the Open-label Period

    Any use of emergency treatment (such as an emergency room visit) was recorded in the patient's diary, along with the date, time, and reason for the emergency treatment. Emergency department visits required some type of rescue action taken, other than the visit itself.

    Measured: From 15 minutes to 12 hours after study drug administration for onset of an episode of ARS during the Open-label Period

  8. Number of Participants Requiring Rescue Medical Care Other Than Medication or Emergency Department Visits During the Open-label Period

    Other rescue medical care consisted of care other than rescue medication or emergency department visits. Each patient's specific criteria for seizure and an episode of acute repetitive seizure (ARS) were determined by the Investigator. Patients and their caregivers were trained to use these criteria to recognize the onset of an episode of ARS and when and how to administer study drug.

    Measured: From 15 minutes to 12 hours after study drug administration for onset of an episode of ARS during the Open-label Period

  9. Mean Score on Caregiver Global Treatment Assessment During the Open-label Period

    Caregiver global evaluation is based on seizure frequency, severity, and overall outcome compared with previous episodes and is rated on a 10-cm visual analogue scale, where 0=much worse and 10=much better. A higher score indicates greater improvement. An episode of acute repetitive seizures (ARS) is defined as an episode of multiple complex, partial, or generalized seizures occurring over a brief period (minutes to 12 hours) with the patient regaining consciousness between seizures, which were readily recognizable by the patient or a trained caregiver. ARS includes seizures sometimes referred to as serial, cluster, crescendo, or stuttering prolonged.

    Measured: Assessments completed at the end of each treated episode of ARS in the Open-label Period

  10. Mean Score on Physician Global Treatment Assessment During the Open-label Period

    Physician global evaluation is based on seizure frequency, severity, and overall outcome compared with previous episodes and is rated on a 10-cm visual analogue scale, where 0=much worse and 10=much better. A higher score indicates greater improvement. An episode of acute repetitive seizures (ARS) is defined as an episode of multiple complex, partial, or generalized seizures occurring over a brief period (minutes to 12 hours) with the patient regaining consciousness between seizures, which were readily recognizable by the patient or a trained caregiver. ARS includes seizures sometimes referred to as serial, cluster, crescendo, or stuttering prolonged.

    Measured: From Visit 2 and subsequent visits in the Open-label Period to discharge or study termination

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Apr 2006 (estimated)
  2. Study startJan 2006
  3. Primary completionJul 2014
  4. Study completionJul 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
234 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00319501
Sponsor's protocol ID
K826-05-3001
Other IDs
B4511001
Status last verified
Jul 2016
First submitted
27 Apr 2006
Last updated
23 Sep 2016
Data monitoring committee
Yes

Publications

  • Abou-Khalil B, Wheless J, Rogin J, Wolter KD, Pixton GC, Shukla RB, Sherman NA, Sommerville K, Goli V, Roland CL. A double-blind, randomized, placebo-controlled trial of a diazepam auto-injector administered by caregivers to patients with epilepsy who require intermittent intervention for acute repetitive seizures. Epilepsia. 2013 Nov;54(11):1968-76. doi: 10.1111/epi.12373. Epub 2013 Sep 20.

    PubMed 24111974

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Vanquix Auto-Injector (Diazepam Injection) in people with Seizures and Epilepsies, Partial, run by Pfizer at 86 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 86 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 16 Aug 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to Next Seizure or Rescue Medication During the Double-blind Period (Kaplan-Meier 50th Percentile) (time frame: From 15 minutes to 12 hours after study drug administration for an episode of ARS during the Double-blind Period). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00319501, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in